Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla-C Dubinsky

Showing results (11-20 of 247) with videos related to

Pageof 25
Sort By:
Pediatric Clinics of North America|November 28, 2017
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future DirectionsElizabeth A Spencer, Marla C Dubinsky
Current Treatment Options in Gastroenterology|May 15, 2003
Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing PhenotypesMarla C. Dubinsky, Phillip P. Fleshner
Current Gastroenterology Reports|May 26, 2009
Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati, Marla C Dubinsky
Journal of Clinical Pharmacology|February 25, 2015
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesDiane R Mould, Marla C Dubinsky
Inflammatory Bowel Diseases|June 8, 2017
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative ColitisAnish Patel, Hinaben Panchal, Marla C Dubinsky
Inflammatory Bowel Diseases|February 21, 2014
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel diseaseElaheh Vahabnezhad, Shervin Rabizadeh, Marla C Dubinsky
Gastrointestinal Endoscopy Clinics of North America|September 17, 2016
The First Endoscopy in Suspected Inflammatory Bowel DiseaseRebecca A Fausel, Asher Kornbluth, Marla C Dubinsky
Alimentary Pharmacology & Therapeutics|August 22, 2022
Review article: guide to tofacitinib dosing in patients with ulcerative colitisPeter M Irving, Yvette Leung, Marla C Dubinsky
Inflammatory Bowel Diseases|June 20, 2018
The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBDElizabeth Spencer, Evan Norris, Chadwick Williams, et al.
Inflammatory Bowel Diseases|July 23, 2013
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseParambir S Dulai, Corey A Siegel, Marla C Dubinsky
Pageof 25

Showing results (11-20 of 247) with videos related to

Sort By:
Pageof 25
Pediatric Clinics of North America|November 28, 2017
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future DirectionsElizabeth A Spencer, Marla C Dubinsky
Current Treatment Options in Gastroenterology|May 15, 2003
Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing PhenotypesMarla C. Dubinsky, Phillip P. Fleshner
Current Gastroenterology Reports|May 26, 2009
Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati, Marla C Dubinsky
Journal of Clinical Pharmacology|February 25, 2015
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesDiane R Mould, Marla C Dubinsky
Inflammatory Bowel Diseases|June 8, 2017
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative ColitisAnish Patel, Hinaben Panchal, Marla C Dubinsky
Inflammatory Bowel Diseases|February 21, 2014
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel diseaseElaheh Vahabnezhad, Shervin Rabizadeh, Marla C Dubinsky
Gastrointestinal Endoscopy Clinics of North America|September 17, 2016
The First Endoscopy in Suspected Inflammatory Bowel DiseaseRebecca A Fausel, Asher Kornbluth, Marla C Dubinsky
Alimentary Pharmacology & Therapeutics|August 22, 2022
Review article: guide to tofacitinib dosing in patients with ulcerative colitisPeter M Irving, Yvette Leung, Marla C Dubinsky
Inflammatory Bowel Diseases|June 20, 2018
The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBDElizabeth Spencer, Evan Norris, Chadwick Williams, et al.
Inflammatory Bowel Diseases|July 23, 2013
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseParambir S Dulai, Corey A Siegel, Marla C Dubinsky
Pageof 25